Navigation and service

Using PET for the Evaluation of Innovative Analgetics with Dual Mode of Action (Dual²PET)

Innovative drugs targeting two modes of action based on one chemical structure are a promising novel therapeutic approach in medicine. These ‚dual modulators’ come with the decisive advantage of avoiding the application of different drugs with individual pharmacodynamics and dosing. Thus, dual modulators prevent patients from problems of differential intake and interactions of medications.

The consortium is funded by the European Union and the federal state of Northrhine Westfalia. It aims at using positron emission tomography (PET), a non-invasive, repeatedly applicable and quantitative method, as a genuine technique in the development and optimization of novel drugs with dual modes of action. This novel approach in drug development is targeting at faster and more predictable means to evaluate and provide innovative drugs.

Project partners are Forschungszentrum Jülich (INM-2, INM-5, INM-9) and the companies Grünenthal (Aachen) and Taros Chemicals (Dortmund). The project is supported by Leitmarktagentur NRW and Projektträger Jülich.